


**Recommendations from the Lothian Formulary Committee (FC)
following Scottish Medicines Consortium (SMC) advice, NICE MTA advice,
(FAF3) unlicensed and off-label medicines and (FAF2) medicines not considered by SMC**

12 – Ear, Nose and Oropharynx

In alphabetical order

Product <i>Manufacturer</i>	Condition being treated	NHS Lothian decision	Date of NHS Lothian decision
Date SMC/NICE Recommendation Report number	For more details see www.scottishmedicines.org.uk/		
azelastine hydrochloride 137micrograms plus fluticasone propionate 50micrograms per actuation nasal spray (Dymista [®] nasal spray) <i>Meda Pharmaceuticals</i> 13.10.14 SMC Report No. 921/13 PRODUCT UPDATE (abbreviated resubmission) Patient Access Scheme	Accepted for use: azelastine hydrochloride plus fluticasone propionate nasal spray (Dymista [®]) is accepted for use within NHS Scotland mfor the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient. For patients in whom the combination of azelastine hydrochloride and fluticasone propionate nasal spray is an appropriate choice of therapy, Dymista [®] provides the two ingredients in a single nasal spray. This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of Dymista [®] . This SMC advice is contingent upon the continuing availability of the Patient Access Scheme in NHS Scotland or a list price that is equivalent or lower.	Included on the LJF as a prescribing note, for the indication in question.	November 2014
fluticasone furoate, 27.5 micrograms /actuation nasal spray (Avamys [®]) <i>GlaxoSmithKline</i> 14.04.09 SMC Report No. 544/09	Accepted for use: fluticasone furoate (Avamys [®]) is accepted for use within NHS Scotland for the treatment of the symptoms of allergic rhinitis in adults, adolescents (12 years and over) and children (6 to 11 years). Evidence to support its efficacy comes from a number of comparator- and placebo-controlled studies conducted in adults and children with seasonal and perennial allergic rhinitis. Prescribers should be aware that the recommended doses of fluticasone furoate are not equivalent, on a microgram per microgram basis, to other fluticasone nasal sprays currently available. Other intranasal steroids are available at a lower cost.	Added to the Additional List.	July 2009
mometasone furoate nasal spray 50micrograms/spray (Nasonex [®]) <i>Schering-Plough</i>	Prophylaxis and treatment of allergic rhinitis; nasal polyps	Added to the Formulary as second choice. Beclometasone nasal spray is first choice. The current second choice (fluticasone nasal spray) has been removed and added to the Additional List.	January 2006
montelukast 10mg tablets (Singulair [®]) <i>Merck, Sharp & Dohme Ltd (MSD)</i> 11.07.05 SMC Report No. 185/05	Restricted use: montelukast (Singulair [®]) is accepted for restricted use within NHS Scotland for the symptomatic relief of seasonal allergic rhinitis (SAR) in adult patients in whom montelukast is indicated in asthma, as add-on oral therapy at steps 3 and 4 of the BTS/SIGN asthma guidelines. Other more effective and cost effective treatments for SAR are available for patients in whom montelukast is not required for the treatment of asthma.	Added to the Additional List.	March 2006

Product Manufacturer Date SMC/NICE Recommendation Report number	Condition being treated For more details see www.scottishmedicines.org.uk/	NHS Lothian decision	Date of NHS Lothian decision
rupatadine (Rupafin®) <i>GlaxoSmithKline</i> 08.03.10 SMC Report No. 612/10 NON SUBMISSION	NOT RECOMMENDED: rupatadine (Rupafin®) is not recommended for use within NHS Scotland for the symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria in adults and adolescents (over 12 years of age). The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland.	NOT RECOMMENDED	
standardised allergen extract of grass pollen from Timothy (<i>Phleum pratense</i>) 75,000 SQ-T per oral lyophilisate (Grazax®) <i>ALK-Abelló Ltd</i> 14.01.08 SMC Report No. 367/07 RESUBMISSION	NOT RECOMMENDED: Standardised allergen extract of grass pollen 75,000 per oral lyophilisate (Grazax®) is not recommended for use within NHS Scotland for the treatment of grass pollen induced rhinitis and conjunctivitis in adult patients with clinically relevant symptoms and diagnosed with a positive skin prick test and/or specific IgE test to grass pollen. Although modest clinical benefit has been shown, the manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.	NOT RECOMMENDED	
tacrolimus (Protopic® / Tacrolimus in Orabase / mouthwash) <i>Astellas/Western Infirmary Glasgow</i>	For recalcitrant oral lichen planus (OLP). 	Added to the Additional List, for Specialist Use only. Tacrolimus for recalcitrant OLP has been categorised RED under the ADTC 'Policy for the use of unlicensed (and off-label use) Medicines in NHS Lothian'. Specialist Use only.	November 2013
timothy grass pollen allergen (GRAZAX®) 75,000 SQ-T oral lyophilisate <i>ALK-Abello Ltd</i> 08.04.13 SMC Report No. 868/13 NON SUBMISSION	NOT RECOMMENDED: timothy grass pollen allergen (GRAZAX®) is not recommended for use within NHS Scotland in Disease-modifying treatment of grass pollen induced rhinitis and conjunctivitis in adults and children (5 years or older), with clinically relevant symptoms and diagnosed with a positive skin prick test and/or specific IgE test to grass pollen. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this extension to the indication. As a result we cannot recommend its use within NHSScotland.	NOT RECOMMENDED	